QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases

HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland, October 9, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.

Click here for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en

Contacts: QIAGEN Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826

Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711

CENTOGENE CEO´s office Doreen Niemann e-mail: [email protected] +49-381-203-652-181

SOURCE Qiagen N.V.

Latest Press Release on Drug News

Happy Fruit Redefines Wellness with THCV-Infused Gummies: A Breakthrough in Cannabinoid Innovation and Metabolic Supplements

Unlocking the Power of THCV: Happy Fruit's New Gummies Suppress Appetites and Provide Metabolic Support * OCEANSIDE, Calif. , April 18, 2024 /PRNewswire/ -- Happy Fruit ...

41st International Conference on Drug Discovery and Drug delivery system

On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...